Search

RP01

It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. … RP01 is a novel anti-IgE immunotherapy for allergic individuals.

MM-093

Research on AFP suggests that it may play a role in modulating the immune system of the mother in order to protect the developing fetus during pregnancy. … MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults

Talmapimod

Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

Trafermin

ALKS 27

ALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD).

Delorazepam

In addition to be long acting, delorazepam is relatively potent, with 1 mg of delorazepam being the equivalent of 10 mg diazepam. It has been approved for marketing in Italy. … It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolite of delorazepam.

Cannabinor

Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.

Dovitinib

Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. … Chiron currently has three ongoing Phase I clinical trials for dovitinib.

CY301

CY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.

Bevirimat

Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. … They also show profound effects on scalp and body hair in humans. Bevirimat targets the protein gag-pol polyprotein.